ImmunityBio, Inc. IBRX Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $113.29M+668% | $14.75M+2,271% | $622K+159% | $240K-74.3% | ||
| $753K— | $0— | $0— | $0— | ||
| $112.54M+663% | $14.75M+2,271% | $622K+159% | $240K— | ||
| 99.3%-0.7pp | 100%0.0pp | 100%0.0pp | 100%— | ||
| —— | $190.14M-18.2% | $232.37M-6.4% | $248.15M+26.6% | ||
| —— | $168.78M+30.2% | $129.62M+26.2% | $102.71M-24.1% | ||
| $369.32M+2.9% | $358.93M-1.1% | $362.87M— | —— | ||
| -$256.03M+25.6% | -$344.18M+5.0% | -$362.25M-3.1% | -$351.3M-6.4% | ||
| -226%+2,108pp | -2,334.2%+55,905pp | -58,239.5%+88,135pp | -146,374.2%-111,012pp | ||
| $51.54M+30.0% | $39.66M-69.3% | $129.2M+103% | $63.52M+328% | ||
| -$98.17M— | —— | -$221.64M-236% | -$65.99M-237% | ||
| $6.41M-19.7% | $7.98M+605% | $1.13M+137% | -$3.09M+24.6% | ||
| -$351.61M+15.0% | -$413.65M+29.2% | -$583.89M-39.9% | -$417.29M-19.3% | ||
| -$135K— | $0+100% | -$40K-218% | $34K+278% | ||
| -$351.4M+15.0% | -$413.56M+29.1% | -$583.2M-40.0% | -$416.57M-20.1% | ||
| -310.2%+2,495pp | -2,804.8%+90,957pp | -93,761.4%+79,808pp | -173,569.6%-136,440pp | ||
| -$0.38+39.7% | -$0.63+45.7% | -$1.16-10.5% | -$1.05-18.0% | ||
| -$0.38+35.6% | -$0.59+49.1% | -$1.16-10.5% | -$1.05-18.0% | ||
| 3.6B+30.8% | 2.8B+47.3% | 1.9B+17.4% | 1.6B+3.0% | ||
| 3.6B+31.1% | 2.8B+47.0% | 1.9B+17.4% | 1.6B+3.0% | ||
| —— | —— | $0— | $0— | ||
| -$43.94M-201% | $43.47M+220% | -$36.2M— | $0— | ||
| -$2.17M— | —— | -$2.22M-202% | -$736K— | ||
| $113.29M+668% | $14.75M+2,271% | $622K+159% | $240K— | ||
| -$256.03M+25.6% | -$344.18M+5.0% | -$362.25M-3.1% | -$351.3M-6.4% | ||
| -$240.5M+26.4% | -$326.63M+5.0% | -$343.74M-3.2% | -$333.04M-5.4% | ||
| -$240.5M+26.4% | -$326.63M+5.0% | -$343.74M-3.2% | -$333.04M-5.4% | ||
| -212.3%+2,003pp | -2,215.2%+53,048pp | -55,263.3%+83,502pp | -138,765.8%-104,928pp | ||
| -$256.03M+25.6% | -$344.18M+5.0% | -$362.25M-3.1% | -$351.3M-6.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is ImmunityBio, Inc.'s revenue?
- ImmunityBio, Inc. (IBRX) generated $141.0M in revenue over the trailing twelve months, up 351.5% year over year.
- Is ImmunityBio, Inc. profitable?
- ImmunityBio, Inc. is not currently profitable: it reported a net loss of $854.5M over the trailing twelve months, a -606.2% net margin.
- What are ImmunityBio, Inc.'s profit margins?
- Gross margin is 99.3% and operating margin is -185.4%, with a -606.2% net margin.
- What is ImmunityBio, Inc.'s earnings per share?
- ImmunityBio, Inc.'s diluted EPS over the trailing twelve months is $-0.85.
- Where does ImmunityBio, Inc.'s income statement data come from?
- Every line is extracted from ImmunityBio, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
